Elevated NQO1 expression in ovarian cancer has been shown to confer resistance to quinone-based chemotherapeutics and promote tumor survival, highlighting the dual role of NRF2 in cytoprotection and oncogenic adaptation (55). This evidence concerns the gene NFE2L2 and ovarian carcinoma.